StockData
Boston Scientific Corp logo

Boston Scientific Corp (BSX) KPIs and segments

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3048% below fair value
$43.03−0.66 (-1.51%)

Close on Nov 17, 2026Market cap $62.36BP/E 17.4Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Boston Scientific · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

Nhìn nhanh KPI của Boston Scientific: 60 chỉ số vận hành, trong đó có Cardiovascular Segment — Worldwide Net Sales, Interventional Cardiology & Vascular Therapies và Watchman (Left Atrial Appendage Closure, lấy từ 259 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Cardiovascular($M)2
3,6243,5033,4773,3433,3453,0852,9422,7312,6372,4452,285
United States($M)
2,1752,1372,1472,0922,0421,8681,7791,5861,4741,3161,251
Int'l($M)
1,4491,3661,3291,2511,3031,2181,1631,1451,1631,1291,034
BSX Reportable Segments4
United States($M)
3,2943,2242,9602,5932,4662,258
Europe, Middle East and Africa($M)
932932793878846773822803
Asia-Pacific($M)
878803802790701684670647
Latin America and Canada($M)
206185175169155159162149
MedSurg($M)2
1,8181,7011,8091,7221,7161,5771,6201,4791,4831,4121,441
United States($M)
1,2511,1471,2371,2021,1831,0931,1131,007992941962
Int'l($M)
567554571519534484506472491470479
Cardiology($M)2
2,6412,6472,4292,2962,1292,0471,8721,751
United States($M)
1,6871,6401,4911,4031,2691,1661,017959
Int'l($M)
9541,007938895859881854792
Interventional Cardiology & Vascular Therapies($M)2
1,3331,2446861,1781,124668661665652614
Int'l($M)
746692429679657450449464457426
United States($M)
586552256499467216212201195189
Electrophysiology($M)2
916905890865840730649527428300240
United States($M)
606603605607587511461366271158111
Int'l($M)
310302285258252219188160157143130
Endoscopy($M)2
793736759747737673691678676642646
United States($M)
491446464462456420424417415395393
Int'l($M)
303290297285281253267261261247251
Peripheral Interventions($M)2
702698656645602590573533
United States($M)
405402376377316308299291
Int'l($M)
297296280268285281274242
Urology($M)2
684646717682676633630532525513527
United States($M)
503465522511499469459379363356362
Int'l($M)
181182195171178165170153162157165
Cardiac Rhythm Management($M)2
585578586578590578566561576575553
United States($M)
349349359354355358349349352354348
Int'l($M)
236229228224235220218213224221204
Watchman($M)2
507506535512486425413380379344344
United States($M)
459462485470446390375342342311312
Int'l($M)
4844504340343838363332
Neuromodulation($M)2
341318333293303271299268282256268
United States($M)
257236253230228204231211214190206
Int'l($M)
8482806375676857686663
Interventional Oncology & Embolization($M)2
283268251228
United States($M)
175170155142
Int'l($M)
108999687
United States($M)
3,4263,2843,3853,2943,2242,9602,8932,5932,4662,2582,213
Int'l($M)
2,0171,9201,9011,7701,8371,7021,6691,6161,6541,5991,513
Emerging Markets($M)
771765758690668684680648595
Cardiovascular($M)
1,1971,1251,0501,1351,0791,068912862782674
MedSurg($M)
598533575566606536563518522485
Cardiovascular Segment — Worldwide Net Sales ($M)($M)7
3,4063,6243,5033,4773,3433,3453,0852,9422,7312,6372,4452,285
Cardiovascular Segment — Organic Net Sales Growth (%)(%)
1.9%7.8%11.2%16.1%19.4%23.2%25.6%27.4%24.6%19.0%16.3%13.3%
Cardiovascular Segment — Operational (Constant Currency) Growth (%)(%)
1.9%7.8%11.2%16.5%21.5%25.5%27.6%29.5%25.1%19.7%17.4%13.8%
Cardiovascular Segment — Reported Net Sales Growth (%)(%)
1.9%8.3%13.5%18.2%22.4%26.8%26.2%28.8%25.0%17.8%15.9%13.9%
Cardiovascular Segment — Foreign Currency Impact (%)(%)
0.0%-0.6%-2.3%-1.7%-1.0%-1.3%1.4%0.8%0.1%1.9%1.6%-0.2%
Cardiovascular Segment — Acquisitions & Divestitures Impact (%)(%)
0.0%0.0%0.0%-0.4%-2.1%-2.3%-2.0%-2.2%-0.4%-0.7%-1.1%-0.5%
Cardiovascular Segment — U.S. Net Sales ($M)($M)2
2,0952,1752,1372,1472,0922,0421,8681,7791,5861,4741,3161,251
Cardiovascular U.S. — Operational Sales Growth (%)(%)
0.2%6.5%14.4%20.7%31.9%38.5%41.9%
Cardiovascular U.S. — Reported Sales Growth (%)(%)
0.2%6.5%14.4%20.7%31.9%38.5%41.9%
Cardiovascular Segment — International Net Sales ($M)($M)3
1,3111,4491,3661,3291,2511,3031,2181,1631,1451,1631,1291,034
Cardiovascular International — Operational Sales Growth (%)(%)
4.7%9.8%6.3%10.0%7.0%9.0%10.9%
Cardiovascular International — Reported Sales Growth (%)(%)
4.8%11.2%12.2%14.3%9.3%12.1%7.9%
Cardiovascular International — Foreign Currency Impact (%)(%)
-0.1%-1.5%-5.8%-4.3%-2.3%-3.1%3.0%
Interventional Cardiology & Vascular Therapies (ICVT) — Worldwide Net Sales ($M)($M)9
1,2731,3331,2441,2021,1351,1781,1241,0911,0471,0401,021
Interventional Cardiology & Vascular Therapies (ICVT) — Organic Net Sales Growth (%)(%)
11.9%12.1%7.8%8.3%3.1%6.8%7.2%
Interventional Cardiology & Vascular Therapies (ICVT) — Operational (Constant Currency) Net Sales Growth (%)(%)
11.9%12.1%7.8%8.3%7.4%11.9%12.0%
Interventional Cardiology & Vascular Therapies (ICVT) — Reported Net Sales Growth (%)(%)
12.1%13.1%10.7%10.2%8.3%13.3%10.1%
Interventional Cardiology & Vascular Therapies (ICVT) — Foreign Currency Impact on Growth (%)(%)
-0.2%-1.0%-2.9%-1.9%-0.9%-1.4%1.9%
Interventional Cardiology & Vascular Therapies (ICVT) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%-4.4%-5.1%-4.7%
Interventional Cardiology & Vascular Therapies (ICVT) — U.S. Net Sales ($M)($M)2
578586552537504499467459397379372
Interventional Cardiology & Vascular Therapies (ICVT) U.S. — Operational Sales Growth (%)(%)
14.6%17.5%18.3%17.1%26.8%31.6%25.5%
Interventional Cardiology & Vascular Therapies (ICVT) U.S. — Reported Sales Growth (%)(%)
14.6%17.5%18.3%17.1%26.8%31.6%25.5%
Interventional Cardiology & Vascular Therapies (ICVT) — International Net Sales ($M)($M)3
695746692665631679657632650661649
Interventional Cardiology & Vascular Therapies (ICVT) International — Operational Sales Growth (%)(%)
9.7%8.2%0.4%1.9%-4.4%0.6%4.2%
Interventional Cardiology & Vascular Therapies (ICVT) International — Reported Sales Growth (%)(%)
10.2%9.9%5.2%5.2%-3.0%2.8%1.3%
Interventional Cardiology & Vascular Therapies (ICVT) International — Foreign Currency Impact (%)(%)
-0.4%-1.7%-4.9%-3.3%-1.5%-2.2%3.0%
Interventional Cardiology (Standalone Sub-Unit) — Worldwide Net Sales ($M)($M)5
818849778
Interventional Cardiology — Constant-Currency Net Sales ($M)($M)
816840756
Interventional Cardiology — Organic Net Sales Growth (%)(%)
19.0%14.9%8.5%10.0%
Interventional Cardiology — Operational Net Sales Growth (%)(%)
19.0%14.9%8.5%10.0%
Interventional Cardiology — Reported Net Sales Growth (%)(%)
19.3%16.1%11.7%12.0%
Interventional Cardiology — Foreign Currency Impact (%)(%)
-0.3%-1.1%-3.1%-2.0%
Vascular Therapies / Peripheral Vascular (Standalone Sub-Unit) — Worldwide Net Sales ($M)($M)6
454484466
Vascular Therapies — Constant-Currency Net Sales ($M)($M)
454481456
Vascular Therapies — Organic Net Sales Growth (%)(%)
1.0%7.6%6.6%6.0%
Vascular Therapies — Operational Net Sales Growth (%)(%)
1.0%7.6%6.6%6.0%
Vascular Therapies — Reported Net Sales Growth (%)(%)
1.2%8.4%9.1%7.0%
Vascular Therapies — Foreign Currency Impact (%)(%)
-0.2%-0.8%-2.4%-1.0%
Vascular Therapies — Acquisitions Impact (%)(%)
0.0%0.0%0.0%0.0%
Watchman (Left Atrial Appendage Closure — LAAC) — Worldwide Net Sales ($M)($M)7
482507506535512486425413380379344345
Watchman (Left Atrial Appendage Closure — LAAC) — Organic Net Sales Growth (%)(%)
-5.9%4.2%18.8%29.0%34.6%28.0%23.7%20.0%17.8%20.0%18.8%22.9%
Watchman (Left Atrial Appendage Closure — LAAC) — Operational (Constant Currency) Net Sales Growth (%)(%)
-5.9%4.2%18.8%29.0%34.6%28.0%23.7%20.0%17.8%20.0%18.8%22.9%
Watchman (Left Atrial Appendage Closure — LAAC) — Reported Net Sales Growth (%)(%)
-5.8%4.3%19.2%29.4%34.8%28.4%23.4%19.9%17.8%19.6%18.5%22.9%
Watchman (Left Atrial Appendage Closure — LAAC) — Foreign Currency Impact on Growth (%)(%)
-0.1%-0.1%-0.4%-0.4%-0.2%-0.3%0.2%0.1%0.0%0.5%0.4%0.0%
Watchman (Left Atrial Appendage Closure — LAAC) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Watchman (Left Atrial Appendage Closure — LAAC) — U.S. Net Sales ($M)($M)2
438459462485470446390376342342311312
Watchman (Left Atrial Appendage Closure — LAAC) U.S. — Operational Sales Growth (%)(%)
-6.8%3.0%18.3%29.1%37.2%30.2%25.6%20.4%17.5%19.5%17.1%23.0%
Watchman (Left Atrial Appendage Closure — LAAC) U.S. — Reported Sales Growth (%)(%)
-6.8%3.0%18.3%29.1%37.2%30.2%25.6%20.4%17.5%19.5%17.1%23.0%
Watchman (Left Atrial Appendage Closure — LAAC) — International Net Sales ($M)($M)3
454844504340343838363333
Watchman (Left Atrial Appendage Closure — LAAC) International — Operational Sales Growth (%)(%)
4.0%17.7%23.7%27.7%10.8%7.8%5.5%16.7%20.5%25.0%36.8%21.7%
Watchman (Left Atrial Appendage Closure — LAAC) International — Reported Sales Growth (%)(%)
4.9%19.3%29.2%31.8%12.7%11.4%3.1%15.4%20.9%20.3%32.4%21.7%
Watchman (Left Atrial Appendage Closure — LAAC) International — Foreign Currency Impact (%)(%)
-0.9%-1.5%-5.5%-4.2%-1.9%-3.7%2.3%1.3%-0.4%4.7%4.4%0.0%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Worldwide Net Sales ($M)($M)7
816916905890865840730649527428300240
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Organic Net Sales Growth (%)(%)
-5.3%9.1%21.7%35.1%62.8%93.7%145.0%171.8%176.7%124.6%71.7%43.1%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Operational (Constant Currency) Net Sales Growth (%)(%)
-5.3%9.1%21.7%35.1%62.8%93.7%145.0%171.8%176.7%124.6%71.7%43.1%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Reported Net Sales Growth (%)(%)
-5.7%9.1%23.9%37.1%64.2%96.1%143.2%170.6%177.0%121.9%70.0%43.9%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Foreign Currency Impact on Growth (%)(%)
0.4%0.0%-2.3%-1.9%-1.4%-2.4%1.8%1.2%-0.3%2.7%1.7%-0.8%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — U.S. Net Sales ($M)($M)2
556606603606607587511461366271158110
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) U.S. — Operational Sales Growth (%)(%)
-8.4%3.1%18.0%31.3%65.8%116.8%224.5%317.8%312.2%218.0%84.8%40.4%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) U.S. — Reported Sales Growth (%)(%)
-8.4%3.1%18.0%31.3%65.8%116.8%224.5%317.8%312.2%218.0%84.8%40.4%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) — International Net Sales ($M)($M)3
259310302285258252219188160157143130
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Operational Sales Growth (%)(%)
1.9%23.1%30.1%44.6%56.1%53.9%57.3%47.4%57.8%50.7%59.5%45.5%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Reported Sales Growth (%)(%)
0.7%22.9%37.8%51.3%60.7%60.5%53.5%45.2%58.3%45.9%56.1%47.0%
Electrophysiology (EP & FARAPULSE Pulsed Field Ablation) International — Foreign Currency Impact (%)(%)
1.2%0.2%-7.6%-6.7%-4.6%-6.6%3.8%2.2%-0.5%4.9%3.3%-1.5%
Cardiac Rhythm Management (CRM) — Worldwide Net Sales ($M)($M)7
568585578587578590578566561576575553
Cardiac Rhythm Management (CRM) — Organic Net Sales Growth (%)(%)
-1.6%-1.6%-2.5%1.4%1.8%1.1%1.4%2.9%1.7%2.9%5.3%5.4%
Cardiac Rhythm Management (CRM) — Operational (Constant Currency) Net Sales Growth (%)(%)
-1.6%-1.6%-2.5%1.4%1.8%1.1%1.4%2.9%1.7%2.9%5.3%5.4%
Cardiac Rhythm Management (CRM) — Reported Net Sales Growth (%)(%)
-1.6%-0.9%0.1%3.6%3.0%2.4%0.4%2.5%1.8%1.9%5.0%6.2%
Cardiac Rhythm Management (CRM) — Foreign Currency Impact on Growth (%)(%)
0.1%-0.8%-2.7%-2.2%-1.2%-1.3%1.0%0.4%-0.1%1.1%0.3%-0.8%
Cardiac Rhythm Management (CRM) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Cardiac Rhythm Management (CRM) — U.S. Net Sales ($M)($M)2
349349349359354355358349349352354349
Cardiac Rhythm Management (CRM) U.S. — Operational Sales Growth (%)(%)
-1.4%-1.7%-2.4%2.8%1.5%1.0%1.0%0.1%-1.7%-1.3%2.5%5.1%
Cardiac Rhythm Management (CRM) U.S. — Reported Sales Growth (%)(%)
-1.4%-1.7%-2.4%2.8%1.5%1.0%1.0%0.1%-1.7%-1.3%2.5%5.1%
Cardiac Rhythm Management (CRM) — International Net Sales ($M)($M)3
220236229228224235220218213224221204
Cardiac Rhythm Management (CRM) International — Operational Sales Growth (%)(%)
-1.8%-1.6%-2.8%-0.9%2.2%1.3%2.1%7.7%7.9%10.1%10.1%5.9%
Cardiac Rhythm Management (CRM) International — Reported Sales Growth (%)(%)
-2.0%0.3%4.1%4.8%5.4%4.8%-0.6%6.5%8.1%7.3%9.2%8.2%
Cardiac Rhythm Management (CRM) International — Foreign Currency Impact (%)(%)
0.2%-1.9%-7.0%-5.7%-3.2%-3.4%2.7%1.1%-0.2%2.8%0.9%-2.2%
Interventional Oncology & Embolization (IO&E) — Worldwide Net Sales ($M)($M)7
267283268263253251228222215214204
Interventional Oncology & Embolization (IO&E) — Organic Net Sales Growth (%)(%)
4.8%11.8%15.2%12.2%11.5%13.2%13.1%
Interventional Oncology & Embolization (IO&E) — Operational (Constant Currency) Net Sales Growth (%)(%)
4.8%11.8%15.2%17.3%16.9%16.2%13.1%
Interventional Oncology & Embolization (IO&E) — Reported Net Sales Growth (%)(%)
5.2%12.9%17.5%18.6%17.6%17.0%12.0%
Interventional Oncology & Embolization (IO&E) — Foreign Currency Impact on Growth (%)(%)
-0.4%-1.1%-2.3%-1.3%-0.7%-0.8%1.1%
Interventional Oncology & Embolization (IO&E) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%-5.1%-5.4%-3.0%0.0%
Interventional Oncology & Embolization (IO&E) — U.S. Net Sales ($M)($M)2
175175170161157155142135131130122
Interventional Oncology & Embolization (IO&E) U.S. — Operational Sales Growth (%)(%)
10.9%12.8%19.8%19.5%20.1%18.8%16.1%
Interventional Oncology & Embolization (IO&E) U.S. — Reported Sales Growth (%)(%)
10.9%12.8%19.8%19.5%20.1%18.8%16.1%
Interventional Oncology & Embolization (IO&E) — International Net Sales ($M)($M)3
921089910296968787848482
Interventional Oncology & Embolization (IO&E) International — Operational Sales Growth (%)(%)
-5.2%10.0%7.8%13.7%11.9%12.0%8.7%
Interventional Oncology & Embolization (IO&E) International — Reported Sales Growth (%)(%)
-4.0%12.9%13.7%17.2%13.6%14.1%5.9%
Interventional Oncology & Embolization (IO&E) International — Foreign Currency Impact (%)(%)
-1.2%-2.9%-5.9%-3.4%-1.8%-2.0%2.8%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Worldwide Net Sales ($M)($M)7
686731697668661665652614
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Organic Net Sales Growth (%)(%)
2.9%8.6%9.0%10.1%13.8%8.7%13.1%9.5%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Operational (Constant Currency) Net Sales Growth (%)(%)
2.9%8.6%9.0%10.1%13.8%8.7%13.1%9.5%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Reported Net Sales Growth (%)(%)
3.7%10.0%6.9%8.8%13.4%5.7%10.3%9.3%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Foreign Currency Impact on Growth (%)(%)
-0.9%-1.4%2.1%1.3%0.5%3.0%2.8%0.2%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — U.S. Net Sales ($M)($M)2
256252232217212201195188
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) U.S. — Operational Sales Growth (%)(%)
20.9%25.4%19.1%15.2%16.2%6.4%6.3%7.1%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) U.S. — Reported Sales Growth (%)(%)
20.9%25.4%19.1%15.2%16.2%6.4%6.3%7.1%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) — International Net Sales ($M)($M)3
429479465451449464457426
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Operational Sales Growth (%)(%)
-5.6%1.4%4.6%7.8%12.7%9.7%16.1%10.6%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Reported Sales Growth (%)(%)
-4.3%3.4%1.7%5.9%12.1%5.3%12.1%10.3%
Interventional Cardiology Therapies (ICTx — Legacy Pre-Q4 2025 Reorg) International — Foreign Currency Impact (%)(%)
-1.3%-2.0%3.0%1.9%0.7%4.3%4.1%0.3%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Worldwide Net Sales ($M)($M)7
2,6412,6472,4292,2972,1292,0471,8721,751
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Organic Net Sales Growth (%)(%)
23.1%27.9%31.2%31.9%29.3%22.0%17.9%14.2%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Operational (Constant Currency) Net Sales Growth (%)(%)
23.1%27.9%31.2%31.9%29.3%22.0%17.9%14.2%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Reported Net Sales Growth (%)(%)
24.0%29.3%29.8%31.1%29.2%20.1%16.5%14.5%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Foreign Currency Impact on Growth (%)(%)
-1.0%-1.4%1.4%0.8%0.1%1.9%1.4%-0.3%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — U.S. Net Sales ($M)($M)2
1,6871,6401,4911,4021,2691,1661,017959
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) U.S. — Operational Sales Growth (%)(%)
32.9%40.7%46.6%46.2%38.3%27.2%15.7%14.2%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) U.S. — Reported Sales Growth (%)(%)
32.9%40.7%46.6%46.2%38.3%27.2%15.7%14.2%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) — International Net Sales ($M)($M)3
9541,007938894859881854792
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Operational Sales Growth (%)(%)
8.6%11.0%12.8%14.6%18.0%16.0%20.6%14.2%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Reported Sales Growth (%)(%)
11.0%14.3%9.8%12.9%17.8%12.0%17.5%14.9%
Cardiology Division Total (Legacy Pre-Q4 2025 Sub-Total: ICTx + Watchman + CRM + EP) International — Foreign Currency Impact (%)(%)
-2.4%-3.3%3.0%1.7%0.2%4.0%3.1%-0.6%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Worldwide Net Sales ($M)($M)7
702698656645602590573533
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Organic Net Sales Growth (%)(%)
6.3%7.0%7.4%12.5%10.3%9.4%11.3%10.2%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Operational (Constant Currency) Net Sales Growth (%)(%)
15.8%17.1%15.8%21.7%12.0%12.3%16.0%12.2%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Reported Net Sales Growth (%)(%)
16.7%18.3%14.4%21.0%11.8%10.2%13.9%12.1%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Foreign Currency Impact on Growth (%)(%)
-0.9%-1.1%1.4%0.8%0.1%2.1%2.1%0.1%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — Acquisitions & Divestitures Impact on Growth (%)(%)
-9.5%-10.2%-8.4%-9.2%-1.7%-2.8%-4.6%-2.1%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — U.S. Net Sales ($M)($M)2
405402376377316308299292
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) U.S. — Operational Sales Growth (%)(%)
28.1%30.3%25.7%29.2%11.6%8.0%9.0%9.6%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) U.S. — Reported Sales Growth (%)(%)
28.1%30.3%25.7%29.2%11.6%8.0%9.0%9.6%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) — International Net Sales ($M)($M)3
297296280268285281274242
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Operational Sales Growth (%)(%)
2.2%2.8%4.9%12.7%12.4%17.2%24.4%15.6%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Reported Sales Growth (%)(%)
4.1%5.2%2.0%11.0%12.1%12.7%19.8%15.3%
Peripheral Interventions (PI — Legacy Pre-Q4 2025 Subsegment) International — Foreign Currency Impact (%)(%)
-1.9%-2.4%2.9%1.7%0.3%4.5%4.5%0.3%
MedSurg Segment — Worldwide Net Sales ($M)($M)5
1,7331,8181,7011,8091,7221,7161,5771,6191,4791,4831,4121,441
MedSurg Segment — Organic Net Sales Growth (%)(%)
0.7%5.4%5.7%6.5%7.6%7.0%5.3%7.0%7.7%7.6%7.8%8.9%
MedSurg Segment — Operational (Constant Currency) Growth (%)(%)
0.7%5.4%5.7%10.2%15.6%14.7%12.8%13.0%10.4%10.1%10.9%10.5%
MedSurg Segment — Reported Net Sales Growth (%)(%)
0.6%5.9%7.8%11.7%16.4%15.7%11.7%12.4%10.3%9.0%10.3%11.1%
MedSurg Segment — Foreign Currency Impact (%)(%)
0.1%-0.5%-2.1%-1.5%-0.8%-1.0%1.1%0.6%0.1%1.0%0.6%-0.6%
MedSurg Segment — Acquisitions & Divestitures Impact (%)(%)
0.0%0.0%0.0%-3.7%-8.0%-7.7%-7.5%-6.0%-2.7%-2.5%-3.1%-1.6%
Endoscopy — Worldwide Net Sales ($M)($M)7
741793736760747737673690678676642645
Endoscopy — Organic Net Sales Growth (%)(%)
-0.6%7.0%6.8%8.2%9.0%7.8%5.5%7.0%7.4%7.9%9.8%10.8%
Endoscopy — Operational (Constant Currency) Net Sales Growth (%)(%)
-0.6%7.0%6.8%8.2%9.0%7.8%5.9%7.6%7.9%8.4%12.1%12.2%
Endoscopy — Reported Net Sales Growth (%)(%)
-0.8%7.6%9.4%10.1%10.1%9.1%4.7%7.0%7.8%7.1%11.4%12.9%
Endoscopy — Foreign Currency Impact on Growth (%)(%)
0.1%-0.7%-2.6%-1.9%-1.1%-1.3%1.2%0.6%0.1%1.3%0.7%-0.7%
Endoscopy — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%-0.4%-0.7%-0.5%-0.5%-2.3%-1.4%
Endoscopy — U.S. Net Sales ($M)($M)2
468491446464462456420423417415395394
Endoscopy U.S. — Operational Sales Growth (%)(%)
1.2%7.6%6.2%9.5%10.8%10.0%6.3%7.5%9.1%8.0%12.6%12.9%
Endoscopy U.S. — Reported Sales Growth (%)(%)
1.2%7.6%6.2%9.5%10.8%10.0%6.3%7.5%9.1%8.0%12.6%12.9%
Endoscopy — International Net Sales ($M)($M)3
274303290296285281253267261261247252
Endoscopy International — Operational Sales Growth (%)(%)
-3.6%6.0%7.7%6.0%6.3%4.3%5.4%7.8%6.0%9.1%11.4%11.2%
Endoscopy International — Reported Sales Growth (%)(%)
-4.0%7.7%14.8%10.9%9.2%7.6%2.2%6.2%5.8%5.9%9.6%13.0%
Endoscopy International — Foreign Currency Impact (%)(%)
0.4%-1.7%-7.0%-4.9%-2.9%-3.3%3.2%1.6%0.2%3.3%1.8%-1.8%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Worldwide Net Sales ($M)($M)7
661684646717682676633630532525513527
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Organic Net Sales Growth (%)(%)
-3.1%0.8%0.5%3.2%5.4%6.3%4.4%7.9%10.4%9.1%9.8%9.9%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Operational (Constant Currency) Net Sales Growth (%)(%)
-3.1%0.8%0.5%12.7%27.5%28.0%24.5%20.1%10.4%9.1%9.8%9.9%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Reported Net Sales Growth (%)(%)
-3.2%1.1%2.1%13.8%28.1%28.9%23.5%19.5%10.3%8.2%9.3%10.5%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Foreign Currency Impact on Growth (%)(%)
0.1%-0.3%-1.6%-1.1%-0.6%-0.8%1.0%0.5%0.1%0.9%0.5%-0.5%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%-9.5%-22.1%-21.7%-20.1%-12.2%0.0%0.0%0.0%0.0%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — U.S. Net Sales ($M)($M)2
492503465522511499469459379363356362
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) U.S. — Operational Sales Growth (%)(%)
-3.8%0.8%-0.8%13.7%34.8%37.4%31.8%26.7%11.1%6.8%9.1%7.9%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) U.S. — Reported Sales Growth (%)(%)
-3.8%0.8%-0.8%13.7%34.8%37.4%31.8%26.7%11.1%6.8%9.1%7.9%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) — International Net Sales ($M)($M)3
169181182195171178165171153162157165
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Operational Sales Growth (%)(%)
-1.2%0.7%4.3%9.9%9.5%7.0%8.1%5.5%8.9%14.4%11.5%14.8%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Reported Sales Growth (%)(%)
-1.4%1.9%10.3%14.1%11.7%9.7%4.8%3.8%8.4%11.3%9.9%16.7%
Urology (Incl. Pelvic Health & Axonics Sacral Neuromodulation) International — Foreign Currency Impact (%)(%)
0.2%-1.2%-6.1%-4.2%-2.2%-2.7%3.4%1.7%0.5%3.2%1.6%-1.9%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Worldwide Net Sales ($M)($M)7
331341318332293303271299268282256269
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Organic Net Sales Growth (%)(%)
13.0%12.2%15.4%9.9%8.6%6.6%6.8%5.5%2.7%3.7%-1.3%2.6%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Operational (Constant Currency) Net Sales Growth (%)(%)
13.0%12.2%15.4%9.9%8.6%6.6%6.8%11.9%17.1%16.2%9.8%7.5%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Reported Net Sales Growth (%)(%)
13.1%12.7%17.4%11.1%9.1%7.2%5.8%11.4%17.0%15.5%9.5%8.0%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Foreign Currency Impact on Growth (%)(%)
-0.1%-0.6%-1.9%-1.2%-0.5%-0.6%0.9%0.5%0.1%0.7%0.3%-0.5%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%-6.4%-14.4%-12.5%-11.2%-4.9%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — U.S. Net Sales ($M)($M)2
255257236252230228204231211214190206
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) U.S. — Operational Sales Growth (%)(%)
11.1%13.1%15.7%9.2%8.8%6.3%7.2%12.2%20.9%16.8%10.5%5.2%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) U.S. — Reported Sales Growth (%)(%)
11.1%13.1%15.7%9.2%8.8%6.3%7.2%12.2%20.9%16.8%10.5%5.2%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) — International Net Sales ($M)($M)3
768482806375676857686663
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Operational Sales Growth (%)(%)
19.9%9.4%14.7%12.2%8.0%7.4%5.4%11.2%5.1%14.1%8.1%16.0%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Reported Sales Growth (%)(%)
20.4%11.8%22.5%17.6%10.3%9.9%1.9%9.1%4.6%11.4%6.9%18.5%
Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation & Pain) International — Foreign Currency Impact (%)(%)
-0.5%-2.4%-7.8%-5.4%-2.3%-2.6%3.6%2.2%0.6%2.7%1.1%-2.5%
Consolidated Total Company — Worldwide Net Sales ($M)($M)5
5,1385,4425,2035,2865,0655,0614,6634,5614,2094,1203,8563,725
Consolidated Total Company — Organic Net Sales Growth (%)(%)
1.5%7.0%9.4%12.7%15.3%17.4%18.2%19.5%18.2%14.7%13.1%13.6%
Consolidated Total Company — Operational (Constant Currency) Net Sales Growth (%)(%)
1.5%7.0%9.4%14.3%19.4%21.6%22.2%23.1%19.5%16.1%15.0%14.5%
Consolidated Total Company — Reported Net Sales Growth (%)(%)
1.5%7.5%11.6%15.9%20.3%22.8%20.9%22.4%19.4%14.5%13.8%14.9%
Consolidated Total Company — Foreign Currency Impact on Growth (%)(%)
0.0%-0.5%-2.2%-1.6%-0.9%-1.2%1.3%0.7%0.1%1.6%1.2%-0.4%
Consolidated Total Company — Acquisitions & Divestitures Impact on Growth (%)(%)
0.0%0.0%0.0%-1.6%-4.2%-4.2%-4.0%-3.6%-1.3%-1.4%-1.9%-0.9%
Cardiovascular — Segment Operating Income ($M)($M)6
1,0161,1971,1251,0101,1451,0791,068912862782674641
Cardiovascular — Segment Operating Margin (%)(%)
29.8%33.1%32.1%34.2%32.1%33.8%31.5%29.4%27.4%
Cardiovascular — Adjusted Segment Operating Margin (%)(%)
29.8%33.1%32.1%30.3%34.2%32.1%33.8%30.6%31.5%28.9%26.9%24.8%
Cardiovascular — Segment Net Sales at Constant Currency ($M)($M)
3,4063,6223,5023,4653,3463,3653,1572,9772,740
Cardiovascular — Total Segment Operating Expenses ($M)($M)5
2,3902,4252,3772,4162,2012,2862,0892,0651,878
Cardiovascular — Total Segment Expenses as % of Segment Sales (%)(%)
70.2%66.9%67.9%69.7%65.8%67.9%66.2%69.4%68.5%
Cardiovascular — Segment Cost of Products Sold (ASU 2023-07, $M)($M)1
1,0271,0651,0671,0399311,048926911838851811
Cardiovascular — Segment Cost of Products Sold (% of Segment Sales)(%)
30.1%29.4%30.5%27.8%31.2%29.3%30.6%31.9%33.0%
Cardiovascular — Segment SG&A Expenses (ASU 2023-07, $M)($M)1
985992959971926915873874791796740
Cardiovascular — Segment SG&A Expenses (% of Segment Sales)(%)
28.9%27.4%27.4%27.7%27.2%27.7%28.9%29.9%30.1%
Cardiovascular — Segment R&D Expenses (ASU 2023-07, $M)($M)1
371359343372338316283276244231228
Cardiovascular — Segment R&D Expenses (% of Segment Sales)(%)
10.9%9.9%9.8%10.1%9.4%9.0%8.9%8.7%9.3%
Cardiovascular — Other Segment Expense Items / Royalties (ASU 2023-07, $M)($M)1
88776665554
Cardiovascular — Other Segment Expense Items (% of Segment Sales)(%)
0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%
Cardiovascular — Segment Depreciation Expense ($M)($M)
97938910589837891757166
Cardiovascular — Segment Goodwill Balance ($M)($M)
10,56910,55810,56010,57410,52810,5509,8419,6069,6849,0579,0199,041
MedSurg — Segment Operating Income ($M)($M)6
545598533554572606536563518522485550
MedSurg — Segment Operating Margin (%)(%)
31.4%32.9%31.3%33.2%35.1%33.3%34.9%34.9%34.2%
MedSurg — Adjusted Segment Operating Margin (%)(%)
31.4%32.9%31.3%31.9%33.2%35.1%33.3%34.4%34.9%34.6%33.8%35.4%
MedSurg — Segment Net Sales at Constant Currency ($M)($M)
1,7351,8181,7001,8031,7231,7251,6091,6361,484
MedSurg — Total Segment Operating Expenses ($M)($M)5
1,1901,2211,1671,2281,1511,1191,0741,074965
MedSurg — Total Segment Expenses as % of Segment Sales (%)(%)
68.6%67.1%68.7%68.1%66.8%64.9%66.7%65.6%65.0%
MedSurg — Segment Cost of Products Sold (ASU 2023-07, $M)($M)1
504526478529483470435457412401381
MedSurg — Segment Cost of Products Sold (% of Segment Sales)(%)
29.1%28.9%28.1%28.0%27.3%27.0%27.8%26.8%26.9%
MedSurg — Segment SG&A Expenses (ASU 2023-07, $M)($M)1
556567557550534521512483440454439
MedSurg — Segment SG&A Expenses (% of Segment Sales)(%)
32.1%31.2%32.8%31.0%30.2%31.8%29.7%30.4%31.0%
MedSurg — Segment R&D Expenses (ASU 2023-07, $M)($M)1
126124127137129120121128113114107
MedSurg — Segment R&D Expenses (% of Segment Sales)(%)
7.2%6.8%7.5%7.5%7.0%7.5%7.6%7.6%7.6%
MedSurg — Other Segment Expense Items / Royalties (ASU 2023-07, $M)($M)1
44525865045
MedSurg — Other Segment Expense Items (% of Segment Sales)(%)
0.3%0.2%0.3%0.3%0.4%0.3%0.0%0.3%0.3%
MedSurg — Segment Depreciation Expense ($M)($M)
3129293129282731272724
MedSurg — Segment Goodwill Balance ($M)($M)
8,1678,0827,9777,7097,6867,5267,5007,4835,3495,3415,3425,347
Total Reportable Segments — Operating Income ($M)($M)7
1,3501,2721,128
Total Reportable Segments — Adjusted Operating Income at Constant Currency ($M)($M)
1,5601,7951,6581,6241,7181,6851,6041,4741,380
Total Reportable Segments — Net Sales at Constant Currency ($M)($M)
5,1415,4405,2025,2685,0695,0904,7664,6144,224
Total Reportable Segments — Combined Segment Expenses ($M)($M)
3,5803,6463,5443,6443,3523,4053,1633,1392,843
Unallocated Corporate Expenses & FX Hedging Impact ($M)($M)
-196-252-199-179-299-286-255-224203153115-581
Unallocated Acquisition, Restructuring, Litigation, Impairment & EU MDR Charges ($M)($M)
-302-132-126-392-146-355-209-351209386124
Unallocated Intangible Amortization Expense ($M)($M)
-234-233-232-228-225-225-219-225-205
Total Reportable Segments — Combined Segment Assets ($M)($M)
12,45612,25911,97711,39111,19110,82910,54010,1778,876
United States — Regional Net Sales ($M)($M)3
3,3093,4263,2843,3853,2943,2242,9602,8932,5932,4662,2582,213
United States — Operational Sales Growth (%)(%)
0.5%6.2%10.9%17.0%27.0%30.7%31.1%30.7%23.5%16.9%12.7%11.4%
United States — Reported Sales Growth (%)(%)
0.5%6.2%10.9%17.0%27.0%30.7%31.1%30.7%23.5%16.9%12.7%11.4%
United States — Foreign Currency Impact (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
International Total (Non-U.S.) — Regional Net Sales ($M)($M)4
1,8292,0171,9201,9011,7701,8371,7021,6691,6161,6541,5991,513
Europe, Middle East & Africa (EMEA) — Net Sales ($M)($M)3
829932932933793878846830773822803749
EMEA — Operational Sales Growth (%)(%)
6.1%4.2%1.2%4.8%-2.0%1.8%7.9%11.6%14.3%16.1%13.3%11.6%
EMEA — Reported Sales Growth (%)(%)
4.4%6.1%10.1%12.4%2.6%6.8%5.5%10.8%15.2%13.7%12.7%14.0%
EMEA — Foreign Currency Impact (%)(%)
1.7%-1.9%-8.8%-7.6%-4.6%-5.0%2.4%0.9%-1.0%2.5%0.6%-2.4%
Asia-Pacific (APAC) — Net Sales ($M)($M)3
797878803788802790701684684670647616
APAC — Operational Sales Growth (%)(%)
-1.1%11.2%12.0%14.8%16.9%15.4%10.6%12.4%12.3%13.2%25.9%17.0%
APAC — Reported Sales Growth (%)(%)
-0.6%11.2%14.7%15.2%17.1%18.0%8.2%11.1%12.1%7.0%18.3%14.8%
APAC — Foreign Currency Impact (%)(%)
-0.4%-0.0%-2.7%-0.4%-0.2%-2.6%2.4%1.2%0.2%6.2%7.6%2.2%
Latin America & Canada (LACA) — Net Sales ($M)($M)3
203206185179175169155155159162149148
LACA — Operational Sales Growth (%)(%)
10.5%16.2%12.0%10.4%9.6%8.9%14.1%12.6%15.1%15.7%12.7%14.6%
LACA — Reported Sales Growth (%)(%)
16.0%22.4%19.0%15.9%10.4%4.0%4.4%4.6%9.0%15.3%17.9%20.8%
LACA — Foreign Currency Impact (%)(%)
-5.5%-6.2%-7.0%-5.5%-0.8%4.9%9.6%8.0%6.1%0.4%-5.1%-6.2%
Emerging Markets — Net Sales ($M)($M)3
771765758690668684680648595
Emerging Markets — Operational Sales Growth (%)(%)
13.0%11.5%12.1%9.8%15.2%16.8%19.3%28.2%18.7%
Emerging Markets — Reported Sales Growth (%)(%)
15.4%11.8%11.6%6.5%12.4%15.2%14.8%22.6%16.3%
Emerging Markets — Foreign Currency Impact (%)(%)
-2.5%-0.2%0.5%3.3%2.8%1.5%4.6%5.5%2.4%
Long-Lived Tangible Assets — United States ($M)($M)3
1,9981,9841,9481,9191,8121,5301,5221,4611,300
Long-Lived Tangible Assets — Ireland ($M)($M)
755752750750707701655631598
Long-Lived Tangible Assets — Costa Rica ($M)($M)
656647640637593574557530373
Long-Lived Tangible Assets — Rest of World ($M)($M)
774743725730683656654672587
Adjusted Gross Profit (Non-GAAP, $M)($M)5
3,4933,8243,6683,7353,5953,5143,3323,2222,9622,8992,6922,621
Adjusted Gross Margin (Non-GAAP, %)(%)
68.0%70.3%70.5%70.7%71.0%69.4%71.5%70.6%70.4%70.4%69.8%70.4%
GAAP Gross Margin, as Reported (%)(%)
66.7%70.7%69.4%69.6%69.9%67.7%68.8%67.9%68.8%69.2%68.7%69.2%
Gross Margin YoY Bridge — Pricing, Volume & Product Mix Impact (bps / %)(%)
-0.3%0.6%0.8%1.8%1.6%2.1%0.9%-0.3%0.5%
Gross Margin YoY Bridge — Foreign Currency Fluctuations Impact (bps / %)(%)
-0.2%-0.4%-0.8%0.2%-0.3%
Gross Margin YoY Bridge — Manufacturing & Other Period Expense Impact (bps / %)(%)
-1.1%2.9%0.7%-0.7%-3.1%-1.9%-0.9%-1.3%-0.9%
Adjusted Operating Income (Non-GAAP, $M)($M)6
1,3641,5431,4591,4441,4191,3991,3501,2511,1471,1191,012990
Adjusted Operating Margin (Non-GAAP, %)(%)
26.5%28.4%28.0%27.3%28.0%27.6%28.9%27.4%27.2%27.2%26.2%26.6%
GAAP Operating Margin, as Reported (%)(%)
16.1%21.6%21.2%15.6%20.7%16.2%19.8%14.8%17.4%12.6%17.5%15.7%
Adjusted Total Operating Expenses (Non-GAAP, $M)($M)
2,1282,2812,2092,2912,1752,1141,9821,9711,8151,7801,6801,631
Adjusted SG&A Expenses (Non-GAAP, $M)2
Adjusted SG&A as % of Net Sales (Non-GAAP, %)(%)
31.8%32.3%32.8%33.1%33.1%32.2%33.2%33.6%33.9%34.1%34.3%34.2%
GAAP SG&A as % of Net Sales (%)(%)
32.7%33.1%34.2%34.7%34.4%33.9%34.2%35.3%37.1%35.1%35.4%37.0%
Adjusted R&D Expenses (Non-GAAP, $M)2
Adjusted R&D as % of Net Sales (Non-GAAP, %)(%)
9.4%9.4%9.4%10.1%9.6%9.3%9.1%9.4%9.1%8.9%9.1%9.2%
GAAP R&D as % of Net Sales (%)(%)
10.1%10.2%9.9%10.8%10.1%10.4%9.5%10.1%9.7%9.3%9.5%9.7%
Royalty Expense as % of Net Sales (%)(%)
0.2%0.2%0.2%0.1%0.2%0.3%0.3%0.2%0.1%0.2%0.2%0.3%
Adjusted Net Income Attributable to Common Stockholders (Non-GAAP, $M)($M)11
1,0631,2751,1891,2011,1241,1271,1211,043937914832817
Adjusted Diluted Earnings Per Share (Non-GAAP, $/sh)
0.730.860.800.800.750.750.750.700.630.620.560.55
Adjusted Pre-Tax Income (Non-GAAP, $M)($M)
1,2401,4231,3471,3451,3031,2891,2431,1641,0821,051932911
Adjusted Effective Tax Rate (Non-GAAP, %)(%)
14.3%10.4%11.7%10.7%12.5%12.5%9.8%10.5%13.2%12.5%13.0%10.0%
Operational Effective Tax Rate (Non-GAAP, %)(%)
17.6%17.3%17.4%14.9%13.9%14.2%13.6%12.3%13.5%13.5%14.0%14.6%
GAAP Effective Tax Rate, as Reported (%)(%)
20.8%14.6%-15.2%4.3%19.5%15.5%16.5%3.9%30.0%19.0%19.0%0.3%
Non-GAAP Adjustment — Intangible Asset Amortization ($M)($M)
234233232228225225219225205213214208
Non-GAAP Adjustment — Acquisition & Divestiture-Related Net Charges ($M)($M)
82918389991381481471434864129
Non-GAAP Adjustment — Restructuring & Restructuring-Related Net Charges ($M)($M)
9442359736161498052504652
Non-GAAP Adjustment — Litigation-Related Net Charges ($M)($M)
8176194
Non-GAAP Adjustment — Goodwill & Intangible Asset Impairment Charges ($M)($M)
39046111276
Non-GAAP Adjustment — EU Medical Device Regulation (MDR) Implementation Costs ($M)($M)
577121110121313121416
Days Sales Outstanding (DSO, days)(ngày)
565152515151525255535455
Days Inventory on Hand (DIOH, days)(ngày)4
178185177168177159178176193187193199
Inventories — Finished Goods ($M)($M)
1,9711,9721,9311,8491,8271,8081,8051,7981,6871,5581,5551,537
Inventories — Work-in-Process ($M)($M)
311277259246245218218193206201188174
Inventories — Raw Materials ($M)($M)
1,035985928849849835843819860849818773
Acquisition Inventory Fair Value Step-Up Amortization ($M)($M)
242593781510000
Adjusted EBITDA (Non-GAAP, $M)($M)7
1,4641,6301,5401,5581,5021,4871,4261,3441,2211,1961,0781,070
Trailing 12-Month (TTM) Adjusted EBITDA ($M)($M)
6,1926,2306,0875,9735,7595,4785,1874,8394,5654,3354,1674,017
GAAP EBITDA ($M)($M)
1,1911,5001,5881,1411,3621,3641,2079901,013778967873
Trailing 12-Month (TTM) GAAP EBITDA ($M)($M)
5,4195,5905,4555,0734,9234,5743,9873,7483,6313,5893,6043,424
Gross Total Debt (EBITDA Reconciliation Basis, $M)($M)
11,95212,62411,02911,43611,60011,58711,30910,74610,88510,57110,6199,102
Gross Debt to Adjusted EBITDA Leverage Ratio (x)
1.902.001.801.902.002.102.202.202.402.402.502.30
Revolving Credit Facility Consolidated Leverage Ratio — Actual (x)
1.952.021.871.922.022.162.212.261.951.972.082.33
Revolving Credit Facility Consolidated Leverage Ratio — Maximum Covenant Limit (x)
3.754.004.254.754.754.753.753.753.75
Contract Liabilities / Deferred Revenue Balance ($M)($M)1
711691686682668662641635618599593577
Revenue Recognized from Beginning Contract Liability Balance ($M)($M)
74636568685457596249
Acquisition Contingent Consideration Liability Carrying Value ($M)($M)1
246257354385378367214171171293273404
Contingent Consideration Fair Value Remeasurement Net Expense (Benefit) ($M)($M)
-32-16-30711-55-1-2321715
Legal & Product Liability Accrual Reserve Carrying Balance ($M)($M)1
370282229242306300316326250251283377
Litigation & Product Liability Settlement Net Charges ($M)($M)
81760194000000
Restructuring Accrual Reserve Balance ($M)($M)1
48592641
Restructuring Charges Incurred ($M)($M)
638316-88310481318
Other Intangible Assets — Gross Carrying Value ($M)($M)8
18,32218,09417,99217,66717,57717,44617,29317,18816,18115,51015,86315,817
Intangible Assets — Technology-Related Gross ($M)($M)
15,25915,06514,98514,69214,63414,53014,40614,32713,43112,84613,22313,207
Intangible Assets — Patents Gross ($M)($M)
510502497493492483481481480476480480
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets ($M)($M)
730770770813813813949494945454
Estimated Future Intangible Amortization — Year 1 ($M)($M)
881893828
Estimated Future Intangible Amortization — Year 2 ($M)($M)
869874757
Estimated Future Intangible Amortization — Year 3 ($M)($M)
831835737
Estimated Future Intangible Amortization — Year 4 ($M)($M)
786787714
Estimated Future Intangible Amortization — Year 5 ($M)($M)
625769690
Operating Lease Liabilities — Total ($M)($M)3
536482466
Operating Lease Right-of-Use (ROU) Assets ($M)($M)
537553547465495492448449426416430439
Operating Leases Weighted-Average Discount Rate (%)(%)
4.1%3.9%4.5%
Undiscounted Future Operating Lease Payments — Total ($M)($M)
656564539
Unrecognized Tax Benefits (UTB) Balance ($M)($M)1
637636609596529531514506493478465467
Unrecognized Tax Benefits That Would Impact Effective Tax Rate if Recognized ($M)($M)
536536512501444447431423417406393395
Axonics, Inc. (Acquired Nov 2024 — Urology) — Total Net Revenue ($M)($M)9
11611591.4110
Axonics — Sacral Neuromodulation (SNM) Worldwide Revenue ($M)($M)2
92.491.271.788.5
Axonics — Sacral Neuromodulation U.S. Revenue ($M)($M)
90.189.169.886.6
Axonics — Sacral Neuromodulation International Revenue ($M)($M)
2.282.141.841.93
Axonics — Bulkamid Urethral Bulking Hydrogel Worldwide Revenue ($M)($M)2
23.823.419.721.2
Axonics — Bulkamid U.S. Revenue ($M)($M)
19.118.315.217.0
Axonics — Bulkamid International Revenue ($M)($M)
4.795.044.514.19
Axonics — Gross Profit ($M)($M)
89.789.169.382.8
Axonics — Cost of Goods Sold ($M)($M)
26.525.422.227.0
Axonics — Research & Development Expense ($M)($M)
13.512.811.19.72
Axonics — Operating Income (Loss) ($M)($M)
-6.273.68-19.21.06
Axonics — Net Income (Loss) ($M)($M)
-0.026.90-19.16.61
Axonics — Operating Cash Flow ($M)($M)
0.9217.0-9.245.63
Axonics — Total Inventories ($M)($M)
11410593.279.9
Silk Road Medical, Inc. (Acquired Sep 2024 — TCAR Vascular) — Total Net Revenue ($M)($M)8
51.248.547.3
Silk Road Medical — Gross Profit ($M)($M)
38.536.534.8
Silk Road Medical — Cost of Goods Sold ($M)($M)
12.712.012.5
Silk Road Medical — Research & Development Expense ($M)($M)
11.910.710.1
Silk Road Medical — SG&A Expense ($M)($M)
43.840.839.1
Silk Road Medical — Operating Loss ($M)($M)
-17.2-14.9-14.4
Silk Road Medical — Net Loss ($M)($M)
-16.6-14.1-13.0
Silk Road Medical — Operating Cash Flow ($M)($M)
-3.38-15.3-8.45
Silk Road Medical — Total Inventories ($M)($M)
29.730.529.9
U.S. FDA 510(k) Premarket Notification Clearances — Boston Scientific (clearances)1
10.004.004.004.006.004.003.005.006.002.003.007.00
U.S. FDA 510(k) Clearances — Total U.S. Medical Device Industry (clearances)
855.00923.00756.00806.00797.00886.00736.00856.00767.00793.00713.00877.00
U.S. FDA Premarket Approval (PMA) Original & Supplement Approvals — Boston Scientific (approvals)1
48.0067.0058.0040.0043.0028.0039.0057.0046.0054.0049.0068.00
U.S. FDA PMA Approvals — Total U.S. Medical Device Industry (approvals)
565.00608.00567.00525.00585.00588.00524.00683.00538.00550.00459.00656.00
U.S. FDA MAUDE Adverse Event MDR Reports — Boston Scientific Total (reports)6
20,320.0020,617.0020,500.0020,508.0019,673.0017,610.0016,030.0016,967.0015,626.0015,919.0016,221.0015,503.00
FDA MAUDE MDR Reports — Boston Scientific Patient Injury Events (reports)
9,593.0010,030.0011,305.0011,502.0010,184.0010,166.009,489.0010,200.009,246.009,289.009,865.009,514.00
FDA MAUDE MDR Reports — Boston Scientific Device Malfunction Events (reports)
10,376.0010,320.008,925.008,832.009,234.007,233.006,262.006,642.006,252.006,448.006,087.005,853.00
FDA MAUDE MDR Reports — Boston Scientific Death Events (reports)
304.00262.00270.00169.00253.00210.00276.00123.00127.00179.00269.00130.00
FDA MAUDE MDR Reports — Total U.S. Medical Device Industry (reports)
1,189,467.00923,529.00811,618.00751,012.00819,444.00632,296.00685,251.00709,498.00699,798.00631,546.00586,309.00573,619.00
U.S. FDA Device Recall Events — Boston Scientific (recalls)
36.009.008.0034.0030.004.0020.0032.0040.0054.006.0018.00
U.S. FDA Device Enforcement Recall Actions — Boston Scientific (actions)
37.008.008.0035.0029.004.0020.0063.009.0058.002.0018.00
NIH ClinicalTrials.gov — Boston Scientific Studies Started in Period (studies)
11.0011.009.0010.008.0012.0010.008.005.0012.008.009.00
U.S. Producer Price Index — Surgical & Medical Instrument Manufacturing (NAICS 339112, index)1
U.S. Census Quarterly Services Survey — Total U.S. Hospital Revenue (NAICS 622, $M)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Net Sales (GAAP, $M)($M)7
5,1385,4425,2035,2865,0655,0614,6634,5614,2094,1203,8563,725
Gross Profit (GAAP, $M)($M)
3,4283,8483,6143,6793,5423,4243,2103,0952,8972,8502,6482,579
Cost of Products Sold (GAAP, $M)($M)
1,7101,5941,5901,6081,5231,6371,4531,4661,3121,2701,2091,147
Selling, General & Administrative Expenses (GAAP, $M)($M)
1,6831,8031,7811,8341,7411,7161,5971,6121,5621,4461,3641,379
Research & Development Expenses (GAAP, $M)($M)
520554516569514526443459407383366363
Operating Income (Loss) (GAAP, $M)($M)
8281,1781,1018251,048819921675733520675584
Net Income (Loss) Attributable to Common Stockholders (GAAP, $M)($M)
5829071,341672755797674565469324495505
Diluted Earnings Per Share (GAAP, $/sh)
0.400.610.900.510.530.450.320.220.33
Operating Cash Flow (GAAP, $M)($M)2
1,0481,4743481,3641,3431,2865411,4561,002813164957
Capital Expenditures (GAAP, $M)($M)
180195177351181157187277179155179267
Stock-Based Compensation Expense ($M)($M)
728783717975746968666359
Total Assets (GAAP, $M)($M)6
45,46145,21644,35143,67342,70741,55940,14039,39538,07837,10836,66935,136
Cash and Cash Equivalents ($M)($M)
6095391,4531,9651,2755347256062,5022,9132,329865
Total Inventories ($M)($M)
3,3173,2353,1172,9432,9212,8612,8672,8102,7532,6082,5612,484
Property, Plant & Equipment, Net ($M)($M)
4,1834,1264,0634,0363,7953,4613,3893,2943,0722,9512,8972,859
Goodwill ($M)($M)
18,73618,64018,53618,28218,21418,07617,34017,08915,03314,39714,36114,387
Other Intangible Assets, Net ($M)($M)
6,8606,9187,0607,0197,1627,2606,5666,6845,7545,4175,8396,003
Total Stockholders' Equity ($M)($M)
25,63024,93025,86424,23323,39422,41822,21221,77020,70820,37119,92619,282

50 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Business Unit × Geography Revenue & Organic Growth Bridge (Groups 1–2): Full disaggregation across Cardiovascular (Interventional Cardiology & Vascular Therapies [ICVT] with standalone Interventional Cardiology and Vascular Therapies sub-units, Watchman, Electrophysiology, Cardiac Rhythm Management, Interventional Oncology & Embolization, plus legacy ICTx, Cardiology, and Peripheral Interventions) and MedSurg (Endoscopy, Urology, Neuromodulation), split by United States, International, and Worldwide with Reported, Foreign Currency, Operational (Constant Currency), M&A, and Organic growth bridges.
  • Segment Operating Profitability & ASU 2023-07 Significant Segment Expenses (Group 3): Resolves the post-FY2019 Segment Operating Income gap in standard segment tables by extracting GAAP Segment Operating Income ($M & %), Constant-Currency Adjusted Segment Operating Income ($M & %), and ASU 2023-07 Segment Cost of Products Sold, Segment SG&A, Segment R&D, and Other Segment Expenses ($M & % of segment sales) for Cardiovascular and MedSurg.
  • Working Capital, Leverage, Clinical/ESG, Subsidiaries & Regulatory Benchmarks (Groups 5–8): Rolling quarterly DSO (56 days in Q3 2026) and DIOH (178 days in Q3 2026), quarterly GAAP/Adjusted EBITDA and Gross Debt / Adjusted EBITDA (1.9x in Q3 2026), 8-year clinical/quality/workforce/EHS/environmental series (FY2018–FY2025), pre-acquisition standalone filings for Axonics (NASDAQ: AXNX) and Silk Road Medical (NASDAQ: SILK), UK statutory gender pay gap filings for Boston Scientific Limited, and monthly/quarterly openFDA (510(k), PMA, Recalls, MAUDE MDR), ClinicalTrials.gov, and FRED series.
  • Consolidated vs. Standalone Assessment: Boston Scientific Corporation reports consolidated financial statements under U.S. GAAP without separate parent-only income statements; subsidiary performance is presented directly from self-reported SEC and UK statutory filings in Group 7.

Không hiện vì thiếu các kỳ gần đây (14)

  • Annual Patients Treated Worldwide ('more than 48 million patients in 2025', 'over 44 million in 2024', 'over 37 million in 2023') — Always disclosed as lower bounds ('more than', 'over', '33+ million') in Annual Reports and Impact Reports; excluded from main table per bound-number rule.
  • Cumulative WATCHMAN Patients Treated ('more than 500,000 / 600,000 patients worldwide') — Disclosed only as cumulative milestone bounds ('more than', 'over') on earnings calls and presentations; excluded per bound-number rule.
  • Cumulative FARAPULSE PFA Patients Treated ('more than 200,000 / 500,000 patients') — Disclosed as cumulative milestone bounds in earnings call commentary; excluded per bound-number rule.
  • Customer-Facing Sales & Marketing Compliance Training Hours ('10,000+ in 2023, 14,000+ in 2024, 16,000+ in 2025') — Reported with '+' lower-bound suffix in 2025 Impact Report Data Pack; excluded per bound-number rule.
  • Active Direct and Indirect Suppliers ('11,000+ suppliers') — Reported with '+' lower-bound suffix in 2025 Impact Report Data Pack; exact Tier 1 (1,148) and Critical Tier 1 (92) counts are included.
  • Global Gender & Multicultural Pay Equity ('99%+' in 2023 and 2025; 'Analysis not completed' in 2024) — Reported as '99%+' bound and only biennially; excluded per bound-number and continuity rules.
  • Remaining Performance Obligations (RPO) in Form 10-K Note A — Not disclosed as a quantitative dollar series because Boston Scientific elects the ASC 606 practical expedient for contracts with original durations of one year or less.
  • Product Warranty Accrual Rollforward — Disclosed in Form 10-K Note A as immaterial to consolidated financial statements without a quantitative table.
  • Segment Operating Profitability & Significant Segment Expenses (ASU 2023-07 & Non-GAAP) › Total Reportable Segments — Operating Income ($M) › Rhythm & Neuro (Legacy Pre-2021 Segment) — Operating Income ($M) › Rhythm & Neuro (Legacy Pre-2021 Segment) — Operating Margin (%)
  • Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Gross Profit (Non-GAAP, $M) › Adjusted Cost of Products Sold (Non-GAAP, $M)
  • Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Operating Income (Non-GAAP, $M) › Adjusted SG&A Expenses (Non-GAAP, $M)
  • Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Adjusted Operating Income (Non-GAAP, $M) › Adjusted R&D Expenses (Non-GAAP, $M)
  • Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Free Cash Flow Conversion (% of Adjusted Net Income) › Operating Cash Flow Conversion (% of GAAP Net Income)
  • Non-GAAP Earnings Bridge, Working Capital Efficiency (DSO / DIOH) & Credit Leverage › Remaining Share Repurchase Authorization ($M)

Dữ liệu cập nhật 2026-11-04.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Boston Scientific

See a number that looks wrong?